Mucobene (Acetylcysteine)

Acetylcysteine is employed as a mucolytic agent to manage conditions characterized by thickened secretions.

• Respiratory tract disorders: Improves clearance of viscous mucus, aiding breathing in conditions such as chronic bronchitis and COPD.
• Oral mucositis: Reduces severity and duration of mucosal ulceration associated with chemotherapy or radiotherapy.
• Upper respiratory infections: Lowers mucus viscosity in the nasal and sinus passages, facilitating drainage and symptom relief.

• Acetylcysteine cleaves disulfide bonds within mucus glycoproteins, breaking down the polymeric network that gives mucus its thickness. This depolymerisation decreases viscosity, enhancing mucociliary transport. Additionally, the compound serves as a precursor for intracellular glutathione, helping to restore antioxidant capacity in epithelial cells and supporting mucosal protection. By replenishing glutathione, acetylcysteine also mitigates oxidative stress, which can further improve airway surface liquid dynamics and reduce inflammatory responses.

Acetylcysteine is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects

• Nausea: mild stomach upset that may occur after oral intake.
• Vomiting: occasional emesis, especially with higher doses.
• Diarrhea: loose stools reported in some patients.
• Abdominal discomfort: cramping or pain in the gastrointestinal tract.
• Skin irritation: redness or itching at buccal or cutaneous application sites.
• Bad taste: transient metallic or sulfurous taste sensation.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction with hives, swelling, and breathing difficulty.
• Bronchospasm: sudden narrowing of airways, particularly in asthmatic individuals.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hepatic dysfunction: elevated liver enzymes indicating possible liver injury.
• Hemolysis: breakdown of red blood cells in susceptible patients.

When considering acetylcysteine therapy, several precautionary measures should be observed.

• Assess renal function: dose adjustment may be needed in patients with impaired kidney clearance.
• Monitor for hypersensitivity: discontinue if signs of rash, swelling, or respiratory distress appear.
• Use cautiously in asthma: observe for bronchospasm during inhalation or oral administration.
• Avoid concurrent activated charcoal: it can reduce acetylcysteine absorption if given within 2 hours.
• Review anticoagulant therapy: acetylcysteine may enhance anticoagulant effects, requiring INR monitoring.
• Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Acetylcysteine can interact with certain medicines, influencing their efficacy or safety.

Major Interactions (Avoid)

• Nitroglycerin: co‑administration may cause profound hypotension and tachycardia.
• Activated charcoal: binds acetylcysteine and markedly reduces its bioavailability.

Moderate Interactions (Monitor Closely)

• Anticoagulants (warfarin, direct oral anticoagulants): acetylcysteine may potentiate anticoagulant effect, requiring coagulation monitoring.
• Chemotherapeutic agents (e.g., cyclophosphamide): may alter drug metabolism; observe for increased toxicity.
• Antibiotics (e.g., quinolones): potential for altered plasma concentrations; monitor therapeutic response.
• Bronchodilators: possible additive bronchodilatory effect; assess respiratory status.